Download PDF
Z Gastroenterol 2008; 46(1): 69-80
DOI: 10.1055/s-2007-963684
Übersicht

© Georg Thieme Verlag KG Stuttgart · New York

Strategien zur Prävention des hepatozellulären  Karzinoms bei der Hepatitis-Virus-Infektion

Strategies for the Prevention of Hepatocellular Carcinoma in the Context of Chronic Viral HepatitisE. Schott1 , A. Bergk1 , T. Berg1
  • 1Med. Klinik m. S. Hepatologie und Gastroenterologie, Charité, CVK, Berlin
Further Information

Publication History

Manuskript eingetroffen: 26.6.2007

Manuskript akzeptiert: 16.10.2007

Publication Date:
11 January 2008 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die durch die Hepatitis-Viren B (HBV) und C (HCV) induzierte Leberzirrhose stellt den Hauptrisikofaktor für die Entwicklung eines hepatozellulären Karzinoms (HCC) dar. Die Prävention der chronischen Hepatitis-Virus-Infektion bzw. der Entstehung einer Leberzirrhose hat daher zentrale Bedeutung für die Primärprävention des HCC. Durch eine konsequente Impfung gegen HBV kann die Rate der HBV-Infektionen signifikant reduziert und die HCC-assoziierte Mortalität gesenkt werden. Wegen des Fehlens eines Impfstoffes gegen HCV müssen sich die Bemühungen zur Primärprävention der HCV-Infektion auf die Reduktion risikoreicher Verhaltensweisen und die Verbesserung hygienischer Bedingungen beschränken. Im präzirrhotischen Stadium einer chronischen HBV- oder HCV-Infektion kann durch eine effektive antivirale Therapie mit dem Ziel eines dauerhaften virologischen Ansprechens die Entwicklung einer Zirrhose bzw. eines HCC wirkungsvoll verhindert werden. Bei Patienten mit bereits bestehender Zirrhose bleibt jedoch selbst bei anhaltender virologischer Remission nach antiviraler Therapie das Risiko für die HCC-Entwicklung erhöht und erfordert weiterhin ein regelmäßiges Screening zur HCC-Früherkennung. Inwiefern virologische Nonresponder hinsichtlich der HCC-Entwicklung von einer antiviralen Dauertherapie profitieren, kann noch nicht sicher beurteilt werden. Die Frühdiagnose der chronischen HBV- und HCV-Infektion stellt daher den entscheidenden Faktor bei der Prävention des HCC dar. Eine Sekundärprävention nach kurativer Resektion bzw. lokal ablativer Therapie durch eine antivirale Therapie scheint die Rate später Rezidive zu senken. Die Lebertransplantation stellt heutzutage die wirksamste sekundär präventive Strategie für ausgewählte Patienten mit HCC dar. Im Anschluss an eine Lebertransplantation spielt das Immunsuppressivum Sirolimus aufgrund seiner zusätzlichen antiproliferativen Eigenschaften möglicherweise eine Rolle in der Sekundärprävention des HCC.

Abstract

Liver cirrhosis induced by HBV and HCV infections is the main risk factor for the development of hepatocellular carcinoma (HCC). Therefore, prevention of chronic infection with hepatitis viruses and prevention of the development of cirrhosis are essential for the primary prevention of HCC. A consequent vaccination program for HBV is suitable to reduce the rate of infections and the HCC-associated mortality. Since no vaccine is available for HCV, the reduction of risky behaviour and the improvement of hygiene standards are the mainstays for prevention of HCV. An efficient antiviral therapy aimed at the durable suppression of the viral load reduces the risk of progression to cirrhosis and development of HCC in precirrhotic stages of chronic HBV or HCV infections. In cirrhotic patients, the risk of developing HCC remains elevated even if a sustained virological response is achieved, thus requiring further screening with the intention of the early detection of HCC. It is too early to judge whether virological nonresponders profit from continued antiviral therapy. Therefore, the early diagnosis of chronic HBV or HCV infection is the single most important factor for the prevention of HCC. Secondary prevention after surgical resection or local ablative therapy may reduce the frequency of late recurrence. Liver transplantation is today the most effective measure of secondary prevention for selected patients with HCC. Due to its antiproliferative effects, the immunosuppressive drug sirolimus may play a role for secondary prevention of HCC following transplantation.

Schlüsselwörter

Leber - Virushepatitis - Hepatitis B - Hepatitis C

Key words

liver - viral hepatitis - hepatitis B - hepatitis C

Literatur

  • 1 Bosch F X, Ribes J, Diaz M. et al . Primary liver cancer: worldwide incidence and trends.  Gastroenterology. 2004;  127 (5 Suppl 1) S5-S16
    Google Scholar
  • 2 Kubicka S, Rudolph K L, Hanke M. et al . Hepatocellular carcinoma in Germany: a retrospective epidemiological study from a low-endemic area.  Liver. 2000;  20 (4) 312-318
    Google Scholar
  • 3 Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures.  J Viral Hepat. 2004;  11 (2) 97-107
    Google Scholar
  • 4 Yang H I, Lu S N, Liaw Y F. et al . Hepatitis B e antigen and the risk of hepatocellular carcinoma.  N Engl J Med. 2002;  347 (3) 168-174
    Google Scholar
  • 5 Chan H L, Hui A Y, Wong M L. et al . Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma.  Gut. 2004;  53 (10) 1494-1498
    Google Scholar
  • 6 Livingston S E, Simonetti J P, McMahon B J. et al . Hepatitis B virus genotypes in alaska native people with hepatocellular carcinoma: preponderance of genotype f.  J Infect Dis. 2007;  195 (1) 5-11
    Google Scholar
  • 7 Tanaka Y, Mukaide M, Orito E. et al . Specific mutations in enhancer II/core promoter of hepatitis B virus subgenotypes C1 / C2 increase the risk of hepatocellular carcinoma.  J Hepatol. 2006;  45 (5) 646-653
    Google Scholar
  • 8 Chen C J, Yang H I, Su J. et al . Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.  Jama. 2006;  295 (1) 65-73
    Google Scholar
  • 9 Pollicino T, Squadrito G, Cerenzia G. et al . Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection.  Gastroenterology. 2004;  126 (1) 102-110
    Google Scholar
  • 10 Fattovich G, Giustina G, Christensen E. et al . Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep).  Gut. 2000;  46 (3) 420-426
    Google Scholar
  • 11 Bruno S, Silini E, Crosignani A. et al . Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study.  Hepatology. 1997;  25 (3) 754-758
    Google Scholar
  • 12 Squadrito G, Pollicino T, Cacciola I. et al . Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients.  Cancer. 2006;  106 (6) 1326-1230
    Google Scholar
  • 13 Colombo M, Kuo G, Choo Q L. et al . Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma.  Lancet. 1989;  2 (8670) 1006-1008
    Google Scholar
  • 14 Fattovich G, Stroffolini T, Zagni I. et al . Hepatocellular carcinoma in cirrhosis: incidence and risk factors.  Gastroenterology. 2004;  127 (5 Suppl 1) S35-50
    Google Scholar
  • 15 Wang L Y, Hatch M, Chen C J. et al . Aflatoxin exposure and risk of hepatocellular carcinoma in Taiwan.  Int J Cancer. 1996;  67 (5) 620-625
    Google Scholar
  • 16 Bressac B, Kew M, Wands J. et al . Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa.  Nature. 1991;  350 (6317) 429-431
    Google Scholar
  • 17 Hsu I C, Metcalf R A, Sun T. et al . Mutational hotspot in the p53 gene in human hepatocellular carcinomas.  Nature. 1991;  350 (6317) 427-428
    Google Scholar
  • 18 Chang M H, Chen C J, Lai M S. et al . Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group.  N Engl J Med. 1997;  336 (26) 1855-1859
    Google Scholar
  • 19 RKI . Epidemiologisches Bulletin Nr. 32.  2003; 
    Google Scholar
  • 20 RKI . Epidemiologisches Bulletin Nr. 46.  2005; 
    Google Scholar
  • 21 GAVI . Global alliance for vaccines and immunization.  , www.gavialliance.org
    Google Scholar
  • 22 Bronowicki J P, Venard V, Botte C. et al . Patient-to-patient transmission of hepatitis C virus during colonoscopy.  N Engl J Med. 1997;  337 (4) 237-240
    Google Scholar
  • 23 Kaufmann M, Bode J C. Risk of hepatitis C virus infection in medical occupations.  Versicherungsmedizin. 1997;  49 (4) 132-134
    Google Scholar
  • 24 Terrault N A. Sexual activity as a risk factor for hepatitis C.  Hepatology. 2002;  36 (5 Suppl 1) S99-105
    Google Scholar
  • 25 Wild C P, Hall A J. Primary prevention of hepatocellular carcinoma in developing countries.  Mutat Res. 2000;  462 (2 - 3) 381-393
    Google Scholar
  • 26 Mommeja-Marin H, Mondou E, Blum M R. et al . Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature.  Hepatology. 2003;  37 (6) 1309-1319
    Google Scholar
  • 27 Lin S M, Sheen I S, Chien R N. et al . Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection.  Hepatology. 1999;  29 (3) 971-975
    Google Scholar
  • 28 Fattovich G, Giustina G, Realdi G. et al . Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP).  Hepatology. 1997;  26 (5) 1338-1342
    Google Scholar
  • 29 Zonneveld van M, Honkoop P, Hansen B E. et al . Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.  Hepatology. 2004;  39 (3) 804-810
    Google Scholar
  • 30 Lin S M, Yu M L, Lee C M. et al . Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma.  J Hepatol. 2007;  46 (1) 45-52
    Google Scholar
  • 31 Papatheodoridis G V, Manesis E, Hadziyannis S J. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B.  J Hepatol. 2001;  34 (2) 306-313
    Google Scholar
  • 32 Lampertico P, Del Ninno E, Vigano M. et al . Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy.  Hepatology. 2003;  37 (4) 756-763
    Google Scholar
  • 33 Camma C, Giunta M, Andreone P. et al . Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach.  J Hepatol. 2001;  34 (4) 593-602
    Google Scholar
  • 34 Colonno R J, Genovesi E V, Medina I. et al . Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection.  J Infect Dis. 2001;  184 (10) 1236-1245
    Google Scholar
  • 35 Liaw Y F, Sung J J, Chow W C. et al . Lamivudine for patients with chronic hepatitis B and advanced liver disease.  N Engl J Med. 2004;  351 (15) 1521-1431
    Google Scholar
  • 36 Jaeckel E, Cornberg M, Wedemeyer H. et al . Treatment of acute hepatitis C with interferon alfa-2b.  N Engl J Med. 2001;  345 (20) 1452-1457
    Google Scholar
  • 37 Manns M P, McHutchison J G, Gordon S C. et al . Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.  Lancet. 2001;  358 (9286) 958-965
    Google Scholar
  • 38 Fried M W, Shiffman M L, Reddy K R. et al . Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.  N Engl J Med. 2002;  347 (13) 975-982
    Google Scholar
  • 39 Poynard T, McHutchison J, Manns M. et al . Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.  Gastroenterology. 2002;  122 (5) 1303-1313
    Google Scholar
  • 40 Hayashi N, Kasahara A. Interferon for decreasing the incidence of hepatocellular carcinoma in patients with chronic hepatitis C.  Oncology. 2002;  62 (Suppl 1) 87-93
    Google Scholar
  • 41 Ikeda K, Saitoh S, Arase Y. et al . Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis.  Hepatology. 1999;  29 (4) 1124-1130
    Google Scholar
  • 42 Ikeda K, Arase Y, Saitoh S. et al . Anticarcinogenic impact of interferon on patients with chronic hepatitis C: a large-scale long-term study in a single center.  Intervirology. 2006;  49 (1 - 2) 82-90
    Google Scholar
  • 43 Bruno S, Stroffolini T, Colombo M. et al . Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study.  Hepatology. 2007;  45 (3) 579-587
    Google Scholar
  • 44 Nishiguchi S, Shiomi S, Nakatani S. et al . Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis.  Lancet. 2001;  357 (9251) 196-197
    Google Scholar
  • 45 Papatheodoridis G V, Papadimitropoulos V C, Hadziyannis S J. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis.  Aliment Pharmacol Ther. 2001;  15 (5) 689-698
    Google Scholar
  • 46 Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases.  Drugs. 2001;  61 (14) 2035-2063
    Google Scholar
  • 47 Windmeier C, Gressner A M. Pharmacological aspects of pentoxifylline with emphasis on its inhibitory actions on hepatic fibrogenesis.  Gen Pharmacol. 1997;  29 (2) 181-196
    Google Scholar
  • 48 Rambaldi A, Gluud C. Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis.  Cochrane Database Syst Rev. 2005;  CD002148
    Google Scholar
  • 49 Orlent H, Hansen B E, Willems M. et al . Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: a randomized phase II trial.  J Hepatol. 2006;  45 (4) 539-546
    Google Scholar
  • 50 Arase Y, Ikeda K, Murashima N. et al . The long term efficacy of glycyrrhizin in chronic hepatitis C patients.  Cancer. 1997;  79 (8) 1494-1500
    Google Scholar
  • 51 Habu D, Shiomi S, Tamori A. et al . Role of vitamin K 2 in the development of hepatocellular carcinoma in women with viral cirrhosis of the liver.  Jama. 2004;  292 (3) 358-361
    Google Scholar
  • 52 Wang J S, Shen X, He X. et al . Protective alterations in phase 1 and 2 metabolism of aflatoxin B 1 by oltipraz in residents of Qidong, People’s Republic of China.  J Natl Cancer Inst. 1999;  91 (4) 347-354
    Google Scholar
  • 53 Luo H, Tang L, Tang M. et al . Phase IIa chemoprevention trial of green tea polyphenols in high-risk individuals of liver cancer: modulation of urinary excretion of green tea polyphenols and 8-hydroxydeoxyguanosine.  Carcinogenesis. 2006;  27 (2) 262-268
    Google Scholar
  • 54 Gelatti U, Covolo L, Franceschini M. et al . Coffee consumption reduces the risk of hepatocellular carcinoma independently of its aetiology: a case-control study.  J Hepatol. 2005;  42 (4) 528-534
    Google Scholar
  • 55 Tanaka K, Hara M, Sakamoto T. et al . Inverse association between coffee drinking and the risk of hepatocellular carcinoma: a case-control study in Japan.  Cancer Sci. 2006;  8 8
    Google Scholar
  • 56 Montella M, Polesel J, La Vecchia C. et al . Coffee and tea consumption and risk of hepatocellular carcinoma in Italy.  Int J Cancer. 2007;  120 (7) 1555-1559
    Google Scholar
  • 57 Larsson S C, Wolk A. Coffee consumption and risk of liver cancer: a meta-analysis.  Gastroenterology. 2007;  132 (5) 1740-1745
    Google Scholar
  • 58 Greten T F, Blum H E, Manns M P. et al . Treatment of hepatocellular carcinoma.  Z Gastroenterol. 2006;  44 (1) 43-49
    Google Scholar
  • 59 Morimoto O, Nagano H, Sakon M. et al . Diagnosis of intrahepatic metastasis and multicentric carcinogenesis by microsatellite loss of heterozygosity in patients with multiple and recurrent hepatocellular carcinomas.  J Hepatol. 2003;  39 (2) 215-221
    Google Scholar
  • 60 Imamura H, Matsuyama Y, Tanaka E. et al . Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy.  J Hepatol. 2003;  38 (2) 200-207
    Google Scholar
  • 61 Sasaki Y, Yamada T, Tanaka H. et al . Risk of recurrence in a long-term follow-up after surgery in 417 patients with hepatitis B- or hepatitis C-related hepatocellular carcinoma.  Ann Surg. 2006;  244 (5) 771-780
    Google Scholar
  • 62 Schwartz J D, Schwartz M, Mandeli J. et al . Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials.  Lancet Oncol. 2002;  3 (10) 593-603
    Google Scholar
  • 63 Lai E C, Lo C M, Fan S T. et al . Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: a randomized controlled trial.  Arch Surg. 1998;  133 (2) 183-188
    Google Scholar
  • 64 Piao C Y, Fujioka S, Iwasaki Y. et al . Lamivudine treatment in patients with HBV-related hepatocellular carcinoma - using an untreated, matched control cohort.  Acta Med Okayama. 2005;  59 (5) 217-224
    Google Scholar
  • 65 Kubo S, Tanaka H, Takemura S. et al . Effects of lamivudine on outcome after liver resection for hepatocellular carcinoma in patients with active replication of hepatitis B virus.  Hepatol Res. 2007;  37 (2) 94-100
    Google Scholar
  • 66 Sun H C, Tang Z Y, Wang L. et al . Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial.  J Cancer Res Clin Oncol. 2006;  132 (7) 458-465
    Google Scholar
  • 67 Lin S M, Lin C J, Hsu C W. et al . Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors.  Cancer. 2004;  100 (2) 376-382
    Google Scholar
  • 68 Kubo S, Nishiguchi S, Hirohashi K. et al . Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial.  Ann Intern Med. 2001;  134 (10) 963-967
    Google Scholar
  • 69 Uenishi T, Nishiguchi S, Tamori A. et al . Influence of interferon therapy on outcome after surgery for hepatitis C virus-related hepatocellular carcinoma.  Hepatol Res. 2006;  36 (3) 195-200
    Google Scholar
  • 70 Kubo S, Hirohashi K, Tanaka H. et al . Risk factors for recurrence after resection of hepatitis C virus-related hepatocellular carcinoma.  World J Surg. 2000;  24 (12) 1559-1565
    Google Scholar
  • 71 Shiratori Y, Shiina S, Teratani T. et al . Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus.  Ann Intern Med. 2003;  138 (4) 299-306
    Google Scholar
  • 72 Mazzaferro V, Romito R, Schiavo M. et al . Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis.  Hepatology. 2006;  44 (6) 1543-1554
    Google Scholar
  • 73 Cornberg M, Protzer U, Dollinger M M. et al . Prophylaxis, Diagnosis and Therapy of Hepatitis-B-Virus- (HBV-)Infection: upgrade of the guideline, AWMF-Register 021 / 011.  Z Gastroenterol. 2007;  45 (6) 525-574
    Google Scholar
  • 74 Muto Y, Moriwaki H, Ninomiya M. et al . Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group.  N Engl J Med. 1996;  334 (24) 1561-1567
    Google Scholar
  • 75 Muto Y, Moriwaki H, Saito A. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma.  N Engl J Med. 1999;  340 (13) 1046-1047
    Google Scholar
  • 76 Lau W Y, Leung T W, Ho S K. et al . Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial.  Lancet. 1999;  353 (9155) 797-801
    Google Scholar
  • 77 Boucher E, Corbinais S, Rolland Y. et al . Adjuvant intra-arterial injection of iodine-131-labeled lipiodol after resection of hepatocellular carcinoma.  Hepatology. 2003;  38 (5) 1237-1241
    Google Scholar
  • 78 Partensky C, Sassolas G, Henry L. et al . Intra-arterial iodine 131-labeled lipiodol as adjuvant therapy after curative liver resection for hepatocellular carcinoma: a phase 2 clinical study.  Arch Surg. 2000;  135 (11) 1298-1300
    Google Scholar
  • 79 Takayama T, Sekine T, Makuuchi M. et al . Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial.  Lancet. 2000;  356 (9232) 802-807
    Google Scholar
  • 80 Abou-Alfa G K, Schwartz L, Ricci S. et al . Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.  J Clin Oncol. 2006;  24 (26) 4293-4300
    Google Scholar
  • 81 Kawata S, Yamasaki E, Nagase T. et al . Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial.  Br J Cancer. 2001;  84 (7) 886-891
    Google Scholar
  • 82 Lersch C, Schmelz R, Erdmann J. et al . Treatment of HCC with pravastatin, octreotide, or gemcitabine - a critical evaluation.  Hepatogastroenterology. 2004;  51 (58) 1099-1103
    Google Scholar
  • 83 Jonas S, Bechstein W O, Steinmuller T. et al . Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis.  Hepatology. 2001;  33 (5) 1080-1086
    Google Scholar
  • 84 Yao F Y, Ferrell L, Bass N M. et al . Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival.  Hepatology. 2001;  33 (6) 1394-1403
    Google Scholar
  • 85 Bismuth H, Majno P E, Adam R. Liver transplantation for hepatocellular carcinoma.  Semin Liver Dis. 1999;  19 (3) 311-322
    Google Scholar
  • 86 Bernal E, Montero J L, Delgado M. et al . Adjuvant chemotherapy for prevention of recurrence of invasive hepatocellular carcinoma after orthotopic liver transplantation.  Transplant Proc. 2006;  38 (8) 2495-2498
    Google Scholar
  • 87 Otto G, Heise M, Moench C. et al . Transarterial chemoembolization before liver transplantation in 60 patients with hepatocellular carcinoma.  Transplant Proc. 2007;  39 (2) 537-539
    Google Scholar
  • 88 Decaens T, Roudot-Thoraval F, Bresson-Hadni S. et al . Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma.  Liver Transpl. 2005;  11 (7) 767-775
    Google Scholar
  • 89 Leckel K, Beecken W D, Jonas D. et al . The immunosuppressive drug mycophenolate mofetil impairs the adhesion capacity of gastrointestinal tumour cells.  Clin Exp Immunol. 2003;  134 (2) 238-245
    Google Scholar
  • 90 Schumacher G, Oidtmann M, Rosewicz S. et al . Sirolimus inhibits growth of human hepatoma cells in contrast to tacrolimus which promotes cell growth.  Transplant Proc. 2002;  34 (5) 1392-1393
    Google Scholar
  • 91 Guba M, von Breitenbuch P, Steinbauer M. et al . Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor.  Nat Med. 2002;  8 (2) 128-135
    Google Scholar
  • 92 Koehl G E, Andrassy J, Guba M. et al . Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice.  Transplantation. 2004;  77 (9) 1319-1326
    Google Scholar
  • 93 Kneteman N M, Oberholzer J, Al Saghier M. et al . Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma.  Liver Transpl. 2004;  10 (10) 1301-1311
    Google Scholar
  • 94 Hojo M, Morimoto T, Maluccio M. et al . Cyclosporine induces cancer progression by a cell-autonomous mechanism.  Nature. 1999;  397 (6719) 530-534
    Google Scholar
  • 95 Donckier V, Troisi R, Toungouz M. et al . Donor stem cell infusion after non-myeloablative conditioning for tolerance induction to HLA mismatched adult living-donor liver graft.  Transpl Immunol. 2004;  13 (2) 139-146
    Google Scholar
  • 96 DKFZ . Krebsatlas.  2006;  , www.dkfz.de/epi/Home_d/Programm/AG/Praevent/Krebshom/main/deutsch/frame5.html
    Google Scholar
  • 97 Llovet J M, Burroughs A, Bruix J. Hepatocellular carcinoma.  Lancet. 2003;  362 (9399) 1907-1917
    Google Scholar
  • 98 Oon C J. Long-term survival following treatment of hepatocellular carcinoma in Singapore: evaluation of Wellferon in the prophylaxis of high-risk pre-cancerous conditions.  Cancer Chemother Pharmacol. 1992;  31 (Suppl) S137-142
    Google Scholar
  • 99 Mazzella G, Accogli E, Sottili S. et al . Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis.  J Hepatol. 1996;  24 (2) 141-147
    Google Scholar
  • 100 International Interferon-alpha Hepatocellular Carcinoma Study Group . Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study.  Lancet. 1998;  351 (9115) 1535-1539
    Google Scholar
  • 101 Yuen M F, Hui C K, Cheng C C. et al . Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications.  Hepatology. 2001;  34 (1) 139-145
    Google Scholar
  • 102 Nishiguchi S, Kuroki T, Nakatani S. et al . Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.  Lancet. 1995;  346 (8982) 1051-1055
    Google Scholar
  • 103 Fattovich G, Giustina G, Degos F. et al . Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP).  J Hepatol. 1997;  27 (1) 201-205
    Google Scholar
  • 104 Valla D C, Chevallier M, Marcellin P. et al . Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment.  Hepatology. 1999;  29 (6) 1870-1875
    Google Scholar
  • 105 Shiratori Y, Ito Y, Yokosuka O. et al . Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival.  Ann Intern Med. 2005;  142 (2) 105-114
    Google Scholar
  • 106 Someya T, Ikeda K, Saitoh S. et al . Interferon lowers tumor recurrence rate after surgical resection or ablation of hepatocellular carcinoma: a pilot study of patients with hepatitis B virus-related cirrhosis.  J Gastroenterol. 2006;  41 (12) 1206-1213
    Google Scholar
  • 107 El-Serag H B. Hepatocellular carcinoma: recent trends in the United States.  Gastroenterology. 2004;  127 (5 Suppl 1) S27-34
    Google Scholar
  • 108 Perz J F, Armstrong G L, Farrington L A. et al . The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide.  J Hepatol. 2006;  45 (4) 529-538
    Google Scholar
  • 109 Chang M H, Shau W Y, Chen C J. et al . Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls.  Jama. 2000;  284 (23) 3040-3042
    Google Scholar
  • 110 Ni Y H, Chang M H, Huang L M. et al . Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination.  Ann Intern Med. 2001;  135 (9) 796-800
    Google Scholar

Dr. Eckart Schott

Med. Klinik m. S. Hepatologie und Gastroenterologie, Charité, CVK

Augustenburger Platz 1

13353 Berlin

Phone: ++ 49/30/4 50 55 30 71

Fax: ++ 49/30/4 50 55 39 03

Email: eckart.schott@charite.de